China faces critical shortage of laboratory primates for pharmaceutical research

China's pharmaceutical sector is experiencing a supply-demand imbalance for laboratory primates, with annual requirements reaching 30,000 units and prices surging to $30,000 per animal. This scarcity threatens to delay drug development timelines and increase R&D costs for domestic biotech firms.